Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patiromer for acute hyperkalemia in the ED (REDUCE)
NCT02933450Phase 4Completed
- Sponsor
- Baylor College of Medicine
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hyperkalemia comparing Patiromer group with Standard of Care group (2 arms). Primary endpoint: Efficacy of Patiromer in Reducing Serum Potassium at 6 hours. Started Aug 2016; status: completed.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on NCT02933450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933450.